Parkinson's Disease Clinical Trial
Official title:
Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients.
Use lay language.
Many decisions involve the possibility of gaining or losing relative to the status quo. The
loss aversion behaviour is a cognitive concept explaining that people are more sensitive to
the possibility of losing objects or money than they are to the possibility of gaining the
same objects or amounts of money.
We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight
this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary
purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by
comparing brain activity in parkinsonian patient with and without treatment with L Dopa,
when they are exposed to mixed (gain/loss) gambles using money.
The second purpose is to highlight the role of a dopamine depletion by comparing patient
without treatment vs healthy paired control.
2 groups :
- 20 parkinsonian patients (tested two times : with and without treatment by L dopa)
- 20 healthy paired control
Description of the protocol for patients :
J0 : Inclusion visit (duration : 4h):
- motor assessment (UPDRS)
- neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin
scale, UPPS, MADRS, Hamilton, LARS).
J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or
without treatment) :
Each acquisition was composed by an orientation sequence+ an anatomic sequence + a
functional sequence.
For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the
MRI acquisitions.
Use lay language.
Many decisions involve the possibility of gaining or losing relative to the status quo. The
loss aversion behaviour is a cognitive concept explaining that people are more sensitive to
the possibility of losing objects or money than they are to the possibility of gaining the
same objects or amounts of money.
We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight
this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary
purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by
comparing brain activity in parkinsonian patient with and without treatment with L Dopa,
when they are exposed to mixed (gain/loss) gambles using money.
The second purpose is to highlight the role of a dopamine depletion by comparing patient
without treatment vs healthy paired control.
2 groups :
- 20 parkinsonian patients (tested two times : with and without treatment by L dopa)
- 20 healthy paired control
Description of the protocol for patients :
J0 : Inclusion visit (duration : 4h):
- motor assessment (UPDRS)
- neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin
scale, UPPS, MADRS, Hamilton, LARS).
J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or
without treatment) :
Each acquisition was composed by an orientation sequence+ an anatomic sequence + a
functional sequence.
For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the
MRI acquisitions.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A |